Background {#Sec1}
==========

The incidence of inadvertent perioperative hypothermia in surgery, defined as a body core temperature (BCT) below 36 °C, is still high \[[@CR1], [@CR2]\]. A shift of thresholds for vasoconstriction and shivering as well as sympathicolysis-related vasodilatation caused by epidural anesthesia (EDA) result in a redistribution of warm blood from the body core to the periphery \[[@CR3]\]. Furthermore, the induction of general anesthesia (GA) aggravates redistribution hypothermia up to 1.5 °C \[[@CR4]\]. Cytoreductive surgery for ovarian cancer is characterized by maximum extent of tumour debulking including deperitonea-lisation and massive volume shifts and losses \[[@CR5]\]. Stabilisation of the BCT, therefore, requires forced air warming and administration of warmed infusions and transfusions. However, maintainance of normothermia is jeopardized by an anesthesia-reduced base metabolic rate and heat production \[[@CR5]\]. Perioperative hypothermia may affect coagulation by altered platelet function \[[@CR6], [@CR7]\] and increase intraoperative blood loss \[[@CR8]\]. Furthermore, hypothermia-related vasoconstriction may impair microperfusion and reduce the oxygen partial pressure and oxygen saturation (StO~2~) in peripheral tissues \[[@CR9]\]. As a result of impaired microperfusion cell metabolism of subcutaneous fat- or skeletal muscle cells, measured in microdialysis (MD), may be affected \[[@CR10]\].

Preoperative forced-air warming (prewarming) of 10 to 60 min at 43 °C \[[@CR11]--[@CR15]\] before induction of GA has been shown to reduce the temperature gradient between body core and periphery \[[@CR16]\] in order to alleviate redistribution hypothermia \[[@CR3], [@CR16]\] and to maintain intraoperative normothermia \[[@CR17]\] in minor surgery (without EDA) \[[@CR11]\] or major abdominal surgery with EDA \[[@CR12]\]. However, these studies required holding areas to realize prewarming and a timely patient flow. From a surgical point of view, in major cytoreductive surgery with a duration of more than 180 min it still remains unclear whether a brief prewarming during insertion of EDA is effective to maintain intra- and postoperative normothermia and to improve intraoperative hemodynamics and microperfusion as well as to reduce postoperative shivering and ventilation \[[@CR18]\].

We hypothesized that a forced-air prewarming interval of 30 min at 43 °C during epidural catheter placement and induction of GA without any changes of the perioperative patient flow (e.g. no treatment in a preoperative holding area) is effective to maintain perioperative normothermia and improve microperfusion during cytoreductive surgery for ovarian cancer.

Methods {#Sec2}
=======

This single-center prospective randomized clinical trial was conducted at the Departments of Anesthesiology and Intensive Care Medicine and Gynecology of the Charité-Universitätsmedizin Berlin, Germany. Ethics approval was obtained from the institutional ethics committee (EA1/348/14, ClinicalTrials.govID: NCT02364219). Women were enrolled if they were of age (\> 18 years), mentally healthy, American Society of Anesthesiologists physical status Class I--III and scheduled to undergo elective major cytoreductive surgery in primary or secondary ovarian cancer under combined epidural and general anesthesia. Exclusion criteria were: heart failure (left ventricular ejection fraction (LV-EF) \< 30%), chronic obstructive pulmonary disease (GINA-Classification \> 3), renal failure (glomerular filtration rate (GFR) \< 50 ml/min) or dialysis, participation in another clinical trial and contraindication of EDA including non-eligibility due to refusal of neuraxial anesthesia.

After written informed consent and before surgery, women were prospectively randomized into prewarming (prewarm) and standard group (standard) using a computer-generated block randomization (Excel, Microsoft Corporation, Redmont, WA, USA). Additionally, a subgroup of the standard- and the prewarm group were randomly assigned for microdialysis (MD) measurements. The randomization was concealed. Randomization was blinded, the anesthesist during surgery was not randomized and the data evaluation took place independently from the surgery anesthesist.

According to randomization, women in the prewarming group received forced-air warming at 43 °C, during the establishment of epidural anesthesia. Prewarming was applied using a forced air warming gown (Bair Paws™ Flex Warming Gown, 3 M™, St. Paul, MN, USA) connected to a forced air warmer (Bair Hugger™, Model 750, 3 M™, St. Paul, MN, USA), which warms the front of the body including upper arms (Fig. [1](#Fig1){ref-type="fig"}a). In the standard treatment group, patients were covered by a cotton blanket for passive insulation without active warming during the insertion of the epidural catheter. Fig. 1**a**) Forced air prewarming during insertion of the epidural catheter; **b**) subcutaneous microdialyses in the upper arm

The perioperative anesthetic setting in both groups was based on the clinical practice and standard operating procedures of the Department. Upon arrival in the operating room (OR), a peripheral vein cannula was inserted and an infusion of balanced crystalloid solution was started under standard monitoring. Body core temperature was taken by using the SpotOn™ temperature system (3 M™; St. Paul, MN, USA) in both groups and throughout the observation period \[[@CR19]\]. Perioperative body core temperatures were manually recorded in the case reporting form (CRF) at admission to the OR (T~1~), insertion of epidural catheter and induction of GA (T~2~) as well as after 15 min (T~3~), 60 min (T~4~), 120 min (T~5~), 180 min (T~6~), at the end of operation (T~7~), on admission to the ICU (T~ICU~) and 2 h postoperatively (T ~ICU2h~). In both groups, a thoracic epidural catheter was inserted in the sitting position (Fig. [1](#Fig1){ref-type="fig"}a). After induction of GA, EDA was established by a bolus followed by a continuous rate of ropivacaine/ sufentanil (CADD™ Solis pump, Smiths Medical, St. Paul, MN, USA). GA was induced using propofol, fentanyl and rocuronium for endotracheal intubation and maintained with sevoflurane with a minimum inspired oxygen concentration of 40% and an end-tidal CO~2~ concentration of 35 to 40 mmHg. Anaesthesia and muscle relaxation was maintained with repetitive bolusses of fentanyl and rocuronium. A central venous line (Arrow Medical Limited, Kington, UK) was placed into the internal jugular vein and blood pressure was measured by an arterial line (Vygon, Ecouen, France). During surgery, all intravenous (i.v.) fluids were infused using an active warming device (Level 1, Hot Line™, Smiths Medicals, St. Paul, MN, USA). Women were warmed by forced air warming of the upper part of the body (Standard-group: 3M™ Bair Hugger™ Intraoperative Blanket; PW-group: 3M™Bair Paws™ Flex Warming Gown) at 43 °C until end of anesthesia. Forced air warming was shortly paused in both groups during disinfection of the belly before surgery. Postoperatively, women were transferred to the post-anesthesia care unit (PACU). If patients showed clinical signs of hypovolemia (such as heart rate (HR) \> 100 bpm, mean arterial pressure (MAP) \< 60 mmHg, increased pulse pressure variation (PPV)) as well as hypovolemic changes in the hemodynamic monitoring (stroke volume variation (SVV), stroke volume (SV) and CO; Flo-Trac™, Edwards Lifesciencess, Irvine, CA, USA) and in case of intraoperative volume- and blood loss, crystalloid infusion, gelatine infusion (500--1000 ml Gelafundin™ 4% BBraun, Melsungen, Germany) and, if needed, fresh frozen plasma (FFP) and red blood cell concentrates (RBC) were given according to the transfusion- and hemodynamic algorithm of the standard operating procedures (SOP) of the Department of Anesthesiology and Intensive Care Medicine \[[@CR20]\]. During surgery, StO~2~ was measured by near-infrared spectroscopy (InSpectra Spot Check, M300™, Hutchinson, MN, USA) on the thenar of the right hand. Central venous and arterial blood gas analysis to determine dCO~2~, lactate and hemoglobin (Hb) were performed every 30 min. Patients were extubated when spontaneous breathing was sufficient, body core temperature \> 35.5 C and no clinical symptoms of hypovolemia or hemodynamic instability. Postoperative pain relief was achieved using a patient-controlled epidural analgesia (PCEA) and women were transferred to PACU for at least 24 h after operation \[[@CR20]\].

For MD, a 60 mm (inlet tubing diameter 1 mm) flexible catheter (63 MD catheter, molecular weight cut-off of 2kD, M Dialysis AB, Stockholm, Sweden) was placed into the subcutaneous fat tissue below the right deltoid muscle after local anesthesia (Fig. [1](#Fig1){ref-type="fig"}b). After perfusion with isotonic sterile fluid (perfusion fluid T1, M Dialysis AB) at a rate of 1 μl/min (MD Pump 106, M Dialysis AB) a dialysate was collected every 30 min (first sample at T~3~) in a 200 μl microvial (M Dialysis AB) and stored at − 20 °C until analysis. At the end of surgery, the catheter was removed while the patient was still unconscious. All MD analysis were performed by the Experimental & Clinical Research Center (ECRC) of the Franz-Volhard-Centrum, Charité-Universitätsmedizin Berlin, Campus Berlin-Buch.

The primary endpoint was defined as body core temperature drop (BCT~drop~) from before epidural catheter placement (T~1~) and after induction of GA (T~2~) in the prewarming or standard group. Intra- and postoperative change of BCT up to 2 h after ICU admission, StO~2~ and hemodynamic parameters (PPV, SVV, SV), MAP, HR, norepinephrine usage, intraoperative transfusion rates (FFP, RBC), arterial lactate as well as the ethanol ratio, the glucose-, lactate- and glycerol concentration via MD were defined as secondary endpoints. In addition, the central venous-arterial dCO~2~, which depends on the CO~2~ production of the tissues and CO, were measured as a marker for microperfusion \[[@CR21]\]. Postoperatively, shivering and postoperative ventilation were obtained.

Sample size calculation was based on the assumption of a minimal difference of 0.5 °C in body core temperature after prewarming compared to no prewarming (standard) \[[@CR11]\]. A sample size of totally 48 patients, divided into two groups, was calculated to provide 80% power for detecting statistically significant difference at a two-tailed significance level of 0.05 (nQuery Advisor**™**, Release 7.0, Stat. Solutions Ltd. & South Bank, Crosse's Green, Cork, Ireland). A dropout rate of 10% of patients not eligible for data sampling was included.

Data are reported as arithmetic mean \[standard deviation (SD)\] or median \[25, 75% percentile\] (after rejection of normal distribution) or frequencies (%). In order to assess differences in body core temperature as the primary outcome at timepoints T~1~-T~7~ the nonparametric (exact) Mann-Whitney-U test was used. Differences between the groups in terms of patient characteristics as well as secondary outcomes were compared with paired or unpaired t-test and chi-squared test. Frequencies were tested by the exact Mantel-Haenszel test (for ordered categories) or the exact Chi-square test (for unordered categories). A two-tailed *p*-value of \< 0.05 was considered statistically significant.

For MD subgroup analysis a sample size of 7 patients for each group was defined according to the study of Rosdahl et al. \[[@CR10]\].

All calculations were performed with R software (version 3.3; R Foundation for Statistical Computing, Vienna, Austria).

The reporting of this RCT follows the updated guidelines for reporting parallel group randomized trials (CONSORT 2010 statement).

Results {#Sec3}
=======

During January 2015 and December 2017 133 women were screened for eligibility. 85 patients did not meet the inclusion criteria (Fig. [2](#Fig2){ref-type="fig"}) and were excluded before randomization, leaving 48 women for randomization (Fig. [2](#Fig2){ref-type="fig"}). Data of 47 women were analyzed, as one woman had to be excluded due to termination of the procedure out of surgical reasons (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2CONSORT flow diagram

Besides a slight difference in height (*p* = 0.047), patient baseline characteristics, comorbidities and the duration of surgery did not differ significantly between the groups (Table [1](#Tab1){ref-type="table"}). In multivariable linear regressions with group and BMI, group and age or group, BMI, and age as independent variables only group showed a significant relationship (*p* \< 0.05) with body core temperature change. Table 1Patient baseline characteristics, comorbidities and duration of surgeryprewarm *n*=24standard *n*= 23Age (Years, mean±SD)54,4(±11,7)61,3(12,1)Weight (kg, mean±SD)73,6(17,6)67,8(10,3)Height (cm, mean±SD)167(4,9)164,0(6,1)\*BMI (mean±SD)26,3(5,8)25,4(4,1)FIGO stage (n, %) I1(4)0(0) II0(0)0(0) III17(68)14(64) IV5(20)4(18)Residual tumor after surgery (n, %): 0 cm18(72)17(77) 0-1 cm5(20)4(18) 1-2 cm1(4)1(5) \>2 cm2(8)0(0)Preoperative fasting (Liquids in hrs, mean±SD)11,3(4,2)11,6(3,8)Preoperative fasting (Solid in hrs, mean±SD)16,7(4,7)16,2(4,8)Coronary artery disease (n,%)0(0)1(4,4)Heart failure (n,%)0(0)0(0)Diabetes mellitus (n,%)1(4,2)1(4,4)Hypothyroidism (n,%)1(4,2)4(17.4)Renal failure (n,%)0(0)1(4,4)Arterial hypertension (n,%)5(20,8)7(30,4)Peripheral arterial vascular disease (n,%)1(4,2)1(4,4)COPD (n,%)1(4,2)1(4,4)Asthma (n,%)3(12,5)2(8,7)Thrombosis (n,%)3(12,5)1(4,4)Hyperthyroidism (n,%)1(4,2)1(4,4)Nicotine abuse (n,%)0(0)1(4,4)Hyperlipoproteinemia (n,%)0(0)3(13)ASA Classification (n,%): 14(16,7)3(13) 212(50)14(60,9) 38(33,3)6(26,1)Duration of surgery^§^ (min, mean ± SD)334±114364±134\**p* \< 0.05; ^§^ incision to suture; *SD* Standard deviation, *BMI* body mass index, *FIGO* International Federation of Gynecology and Obstetrics, *COPD* chronic obstructive pulmonary disease, *ASA* American Society of Anesthesiologists

Regarding the primary endpoint, the body core temperature change from T~1~ (before) to T~2~ amounted to 0.35 °C in the prewarm group and 0.9 °C in the standard group (Fig. [3](#Fig3){ref-type="fig"}) with a significant difference (ΔT) at T~2~ = 0.55 °C (*p* \< 0.005) between both groups (Fig. [3](#Fig3){ref-type="fig"}). No significant difference in baseline body core temperature (T~1~) was measured (Fig. [4](#Fig4){ref-type="fig"}). After a further decrease of the BCT between T~2~ and T~3~ with a significant ΔT~3~ of 0.85 °C (*p* \< 0,001) (Fig. [4](#Fig4){ref-type="fig"}) the BCT increased in both groups during the operation (Fig. [4](#Fig4){ref-type="fig"}). The core temperature remained higher in the prewarm group over the entire observation period with a significant ΔT at all time points from (ΔT~4~ = 0.9 °C up to ΔT~7~ = 0.95 °C, *p* \< 0,001, Fig. [4](#Fig4){ref-type="fig"}). At T~ICU~ and at T~ICU2h~ the body core temperatures in the PREWARM group were also higher than in the standard group (Fig. [5](#Fig5){ref-type="fig"}). One woman in the prewarm group suffered from hypothermia (\< 36 °C) temporarily while 17 women in the standard group were hypothermic at one time point and/or over the entire intraoperative observation period (*p* \< 0,001). At T~ICU~ six women in the standard group, but none in the prewarm group were subject to postoperative ventilation (*p* \< 0.001) due to hypothermia at a median core temperature of 34.9 °C (34.8; 35.0). Three women in the standard group at T~ICU~ only, but none in the PREWARM group experienced postoperative shivering (*p* \> 0.05). Fig. 3Primary endpoint: Body core temperature drop between T~1~ and after induction of general anesthesia T~2~ with (prewarm) or without (standard) prewarming \[median and quartile (25%; 75%)\] Fig. 4Secondary endpoints: Body core temperature before prewarming (T~1~) and during operation (T~3~ to T~6~) and at the end of surgery (T~7~) \[median and quartile (25%; 75%); \* *p* \< 0,001\] Fig. 5Secondary endpoints: Body core temperature at T~ICU~ and T~ICU2h~

StO~2~ increased from 86% (T~3~) to 88% (T~7~) in the prewarm group and was slightly, but not significantly, higher compared to 82% (T~3~) and 85% (T~7~) in the standard group. In both groups, the dCO~2~ did not change intraoperatively (median: prewarm 6.25 mmHg; standard 6.15 mmHg). Hemodynamic parameters such as SVV, SV and PPV as well as MAP, HR and norepinephrine concentration varied temporarily, depending on the volume changes in both groups, but without any significant differences between both groups at T~3~, T~4~ and T~5~ (Table [2](#Tab2){ref-type="table"}). FFP- and RBC transfusion were used in both groups with a non-significant difference between the groups (Table [2](#Tab2){ref-type="table"}). The intraoperative arterial lactate concentration varied within the scope of 6 mg/dl (T~3~) to 7.5 mg/dl (T~7~) without significant differences between both groups. Table 2Secondary endpoints: Intraoperative hemodynamic parameters at T~3--5~ and total amount of transfusion at the end of surgeryprewarm \[mean; (SD)\]standard \[mean; (SD)\]MAP (mmHg) T~3~80(±12)77(±18) T~4~77(±10)74(±17) T~5~78(±9)75(±17)HR (bpm) T~3~62(±13)60(±15) T~4~68(±12)65(±15) T~5~72(±16)71(±19)SVV (%) T~3~9(±3)8(±3) T~4~9(±3)9(±3) T~5~9(±3)9(±3)SV (ml) T~3~69(±12)67(±16) T~4~74(±18)73(±21) T~5~81(±21)77(±24)PPV (%) T~3~7(±3)7(±3) T~4~9(±3)8(±3) T~5~9(±5)9(±5)Norepinephrine (μg/kg/min) T~3~0.03(± 0.02)0.03(±0.02) T~4~0.06(±0.04)0.06(±0.04) T~5~0.07(±0.05)0.07(±0.04)Transfusion (ml) FFP at T~7~3500(±2300)3700(±2200) RBC at T~7~1000(±600)1000(±900)\**p* \< 0.05; *MAP* mean arterial pressure, *HR* heart rate, *SVV* Stroke volume variation, *SV* Stroke volume, *PPV* pulse pressure variation, *FFP* fresh frozen plasma, *RBC* red blood cells concentrates

For the ethanol ratio, the glucose-, lactate- and glycerol concentration \[median (25. quartile/75. quartile)\] measured by MD from T~3~ to T~7~, no significant differences were detectable between the groups. On closer view, the ethanol ratio (Fig. [6](#Fig6){ref-type="fig"}) was temporarily reduced in the prewarm compared to the standard group, with comparable results at the end of surgery (T~6~). The glucose concentration deferred from 2.05 (0.36/0.36) mmol/l in the prewarm group versus 1.02 (0.42/0.59) mmol/l in the standard group at T~3~ and proceeded almost similar in both groups between 1.51 (0.44/0.87) and 2.1 (1.35/0.35) mmol/l from T~4~ to T~7~. The glycerol concentration decreased continuously from 315 (163/278) μmol/l at T~3~ to 191 (21/185) μmol/l at T~7~ in the prewarm group and from 245 (106/187) μmol/l at T~3~ to 119 (52/131) μmol/l at T~7~ in the standard group. The lactate concentration of 0.66 (0.17/0.07) mmol/l at T3 in the prewarm group was higher compared to 0.48 (0.25/0.18) mmol/l in the standard group and both concentrations aligned at 0.6 (0.17/0.02) mmol/l at T~6~. Fig. 6Secondary endpoints: Ethanol ratio in MD before prewarming (T~1~) and during operation (T~4~to T~6~) and at the end of surgery (T~7~) \[median and quartile (25%; 75%)\]

Discussion {#Sec4}
==========

In this study a forced-air prewarming interval at 43 °C during epidural catheter placement and induction of GA showed efficacy to reduce core temperature drop and to maintain intraoperative normothermia during cytoreductive surgery not only throughout extended surgery but also at ICU admission and two hours thereafter. Furthermore, prewarming reduced the risk of postoperative ventilation due to hypothermia at the end of surgery. Microdialysis and StO~2~ showed better results for the prewarming group, however, this did not reach statistical significance. A reason for this may have been, that all hemodynamic parameters, transfusion rates, and dCO~2~ were not different in either study group. Nevertheless, small sample size for secondary outcomes should be taken into account for further discussions.

In a prospective randomized trial in 99 patients undergoing major abdominal surgery, Horn et al. \[[@CR12]\] analyzed the effects of prewarming over 15 min before and after EDA versus 15 min after EDA or no prewarming. In contrast to our study, forced-air prewarming was performed at 44 °C in a preoperative care unit before and after EDA, which requires higher logistical and staff demands than our approach \[[@CR12]\]. Nevertheless, despite pre- and intraoperative forced-air warming the drop in body core temperature with induction of GA still occurs, which can be significantly alleviated by prewarming, which is in line with earlier results \[[@CR12], [@CR22]\].

At ICU admission only six women of the standard group but none in the prewarming group were mechanically ventilated on ICU because of hypothermia. These findings are in line with the findings of Horn et al. who measured a 34% postoperative ventilation rate in non-prewarmed patients, which indicates the importance of temperature management for ventilation times after surgery. Even 2 h after ICU admission prewarmed women of our study had a higher body core temperature without any shivering. Our data suggest, that the greater body core temperature drop after induction of GA in the standard seems to be irreversible in spite of all intraoperative approaches, such as intraoperative forced air warming, warm fluids etc., to warm up the patients during surgery effectively.

We hypothesized that StO~2~, dCO~2~, arterial lactate and parameters of MD may be useful as surrogate parameters to measure an improved microperfusion in prewarmed and normothermic patients. These markers did not differ significantly, but showed a trend in favor of the prewarm group, which may indicate the need for further studies powered to detect a difference in microcirculation parameters.

We measured a non-significant difference in StO~2~ in favor of the prewarmed patient group~.~ It still remains unclear if this effect is caused by mild hypothermia-induced vasoconstriction and consecutive hypoperfusion and could be prevented by measures to maintain normothermia \[[@CR23]\].

Our MD data could suggest that the tendency of a temporarily reduced ethanol ratio in prewarmed women after induction of GA and during the first hours of operations may represent an improved tissue perfusion \[[@CR10]\]. After normothermia is reestablished due to intraoperative forced-air- warming and warmed transfusion/iv-fluids, the ethanol ratios showed similar values. This is consistent with the other microdialysis parameters. In 13 healthy volunteers, Rosdahl et al. demonstrated that the availability of glucose as a substrate for cell metabolism in subcutaneous fat tissue is dependent on tissue perfusion \[[@CR10]\]. Therefore, the glucose recovery rate in MD acts approximately inverse to the ethanol ratio \[[@CR10]\]. This might explain the increased glucose concentration in the prewarmed group at the beginning of surgery when perfusion may be improved due to the higher body core temperature compared to the standard group. Moreover, an increase of the lactate concentration in MD represents hypoperfusion and oxygen deficit in the subcutaneous tissue, as Bahlmann et al. demonstrated after 15--60 min of aortic clamping \[[@CR24]\]. Potential hypoperfusion of the subcutaneous tissue due to reduced body core temperature did not result in an increase of the lactate concentration in the standard group with MD. On the other hand, the glycerol concentration in MD represents increased metabolic stress and lipolytic activity in the standard group \[[@CR24]\]. Unfortunately and similar to lactate, the concentration remained without significant changes and differences between the groups. It may be hypothesized that mild hypothermia or reduced body core temperature are not very likely to result in a detectable increase of lactate and glycerol in MD. Nevertheless, the MD parameters give a first impression of temperature-related effects on microperfusion and that MD may be a promising technique to identify surrogate parameters for the impact of hypothermia. So far, no comparable data of MD in dependence of changes in body core temperature are published.

Limitations {#Sec5}
===========

Our study has a few limitations: Firstly, the study was powered in regards to primary outcome. In terms of secondary outcome, the study was not powered to detect significant changes, but may allow for an estimation of the number of patients needed for upcoming investigations on microperfusion and MD. Secondly, StO~2~ was evaluated without reference values of an accompanied vascular occlusion test on the upper arm due to potential disruption and damage to the microdialysis catheter, which was inserted on the same side. Lastly, prewarming did not allow a blinding at all times. A concealed randomization was performed. Furthermore the anesthesiologist in charge of the patient was not involved in the collection of study related data. So the likelihood of bias was reduced.

Conclusion {#Sec6}
==========

In conclusion, forced-air prewarming at 43 °C during epidural catheter placement and induction of GA without interfering with the perioperative routine setting is effective to reduce the core temperature drop. Furthermore, prewarming maintains intraoperative normothermia until the end of surgery and up to two hours after ICU admission without any shivering or mechanically ventilation due to hypothermia postoperatively. A statistically significant impact of prewarming on microperfusion as measured by MD could not be detected by this study. However, reduced ethanol ratio and increased glucose concentration in the microdialysis as well as an increased tissue oxygenation may point to a better maintained microperfusion in prewarmed patients compared to those receiving standard treatment. The use of hemodynamic parameters, transfusion rates, StO~2~, dCO~2~ and MD parameters as surrogate parameters influencing microperfusion should be controlled in further randomized, controlled studies investigating the impact of temperature management in surgical patients.

BCT

:   body core temperature

BCT~drop~

:   drop in body core temperature

CO

:   cardiac output

CRF

:   case reporting form

dCO~2~

:   carbon dioxide difference

ECRC

:   Experimental & Clinical Research Center

EDA

:   Epidural anesthesia

FFP

:   fresh frozen plasma

GA

:   General anesthesia

GFR

:   glomerular filtration rate

GINA

:   Global Initiative for Asthma

HR

:   heart rate

i.v.

:   intravenous

ICU

:   Intensive Care Unit

LV-EF

:   left ventricular ejection fraction

MAP

:   mean arterial pressure

MD

:   microdialysis

OR

:   operating room

PACU

:   post-anesthesia care unit

PCEA

:   patient-controlled epidural analgesia

PPV

:   pulse pressure variation

PW

:   prewarming

RBC

:   red blood cell concentrates

SD

:   standard deviation

SOP

:   standard operating procedures

StO~2~

:   tissue oxygenation

SV

:   stroke volumen

SVV

:   stroke volume variation

T~1~

:   Temperature at time before induction of anesthesia

T~2~

:   Temperature after induction of anesthesia

T~3~

:   Temperature after 15 min of induction of anesthesia

T~4~

:   Temperature after 60 min of induction of anesthesia

T~5~

:   Temperature after 120 min of induction of anesthesia

T~6~

:   Temperature after 180 min of induction of anesthesia

T~7~

:   Temperature at the end of operation

T~ICU~

:   Temperature on admission to the ICU

T~ICU2h~

:   Temperature until 2 h after ICU admission

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Not applicable

Study presentation {#FPar1}
==================

This trial was presented in parts at the annual meetings of the American Society of Anesthesiologists 2017 and the European Society of Anesthesiology 2018.

Substantial contributions to conception and design: LK, CvH, PN. Acquisition of data: PN, TB, SC, MB. Analysis and Interpretation of data: AB, JS, MB, CS, AH, CvH. Drafting the manuscript: LK, AB. Revision of the manuscript: PN, TB, SC, JS, MB, CS, AH, CvH. Final approval: LK, PN, TB, SC, JS, AB, MB, CS, AH, CvH. Agreement to be accountable for all aspects of the work: LK, PN, TB, SC, JS, AB, MB, CS, AH, CvH. All Authors meet the criteria for authorship according to the ICMJE guidelines.

This investigator initiated trial was funded by 3 M Deutschland GmbH without any involvement of the funding body on study design, data collection, analysis, interpretation of data and in writing the manuscript. The corresponding author had full access to all study data.

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. The complete trial protocol for this investigator-initiated trial is available in German only and can be requested by the corresponding author.

This trial was performed in accordance with the Declaration of Helsinki and was approved by the local ethics board (Ethics Committee of Charité-Universitätsmedizin Berlin) -- registration number: EA1/348/14.

All patients gave written informed consent, prior to entering the study.

Not applicable

PN, TB, SC, AB, JS, MB, AH have no conflict of interest. LK reports grants from 3 M during the conduct of the study; personal fees from HICC Deutschland GbR., Novo Nordisk, Sintetica, CSL Behring, outside the submitted work. CvH reports personal fees from Bayer AG, CSL Behring, Boehringer Ingelheim, Pfizer GmbH, Bristol Myers Squibb, Shire, Ferring GmbH, Sanofi Aventis, Mitsubishi Pharma, Novo Nordisk, HICC GbR, grants and personal fees from Daiichi Sankyo, outside the submitted work.

CS received funding from European Union funded seventh framework research program (FP7/2007--2013), under the grant agreement No. HEALTH-F2--2014-60246, Bio Cog, grants from Dr. Köhler Chemie GmbH, AppAdventure, J&P Medical Research Ltd., Pharmaceutical Research Associate GmbH, Delcath Systems Inc., INC Research UK Ltd., La Jolla Pharmaceutical Company, ARIDIS Pharmaceutical Inc., B. Braun Melsungen AG, Drägerwerk AG & CoKGaA, Grünenthal GmbH, Infectopharm GmbH, Sedana Medical Ltd., Arbeitsgemeinschaft industrieller Forschungsvereinigungen "Otto von Guericke" e.V. (AiF)/German Federation of Industrial Research Associations, Berufsverband deutscher Anästhesisten e.V. (BDA)/ Professional Associationof German Anaesthesiologists, Deutsche Forschungsgemeinschaft/ German Research Society, Deutsches Zentrum für Luft- und Raumfahrttechnik e.V. (DLR)/German Aerospace Center, Einstein Stiftung Berlin/Einstein Foundation Berlin, European Society of Anaesthesiology, Gemeinsamer Bundesausschuss/Federal Joint Commitee (G-BA), inneruniversitäre Forschungsförderung/Inner university grant, Projektträger im DLR/Project Management Agency, Stifterverband/Non-Profit Society Promoting Science and Education, WHOCC, Westfälische Wilhelms- Universität Münster/DFG, AbbVie Deutschland GmbH & CoKG, Aguettant Deutschland GmbH, MAQUET Vertrieb und Service Deutschland GmbH, Orion Pharma GmbH, Philips Electronics Nederland B.V., Sintetica GmbH, Baxter Deutschland GmbH, Biotest AG, Cytosorbents Europe GmbH, Edwards Lifesciences Germany GmbH, Fresenius Medical Care, Masimo Europe Ltd., Medtronic GmbH, Pfizer Pharma PFE GmbH, European Commission, BMUB (Bundesministerium für Umwelt, Naturschutz und nukleare Sicherheit), personal fees from B. Braun Melsungen AG, Georg Thieme Verlag; outside the submitted work. CS has a patent 10 2014 215 211.9 pending, a patent application No. PCT/EP2015/067730 pending to Graft Gesellschaft von Architekten mbH and a patent application No. PCT/EP2015/067731 pending to Graft Gesellschaft von Architekten mbH.

All authors report no conflict of interest relating to this work.
